Lantheus Holdings logo

Lantheus HoldingsNASDAQ: LNTH

Profile

Sector:

Healthcare

Country:

United States

IPO:

25 June 2015

Next earnings report:

06 November 2024

Last dividends:

N/A

Next dividends:

N/A
$7.47 B
-13%vs. 3y high
91%vs. sector
-92%vs. 3y high
31%vs. sector
-52%vs. 3y high
89%vs. sector
-43%vs. 3y high
61%vs. sector

Price

pre-market | 8 min ago
$107.52-$3.31(-2.99%)

Dividend

No data over the past 3 years
$394.09 M$371.68 M
$394.09 M$62.07 M

Analysts recommendations

Institutional Ownership

LNTH Latest News

Lantheus Applauds CMS' CY25 Rule to Enhance Payment for Specialized Diagnostic Radiopharmaceuticals, Advancing Patient Access and Care
globenewswire.com04 November 2024 Sentiment: POSITIVE

BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services' (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and ensures broad patient access to specialized diagnostic radiopharmaceuticals by improving the accuracy of payment amounts for these products.

Lantheus to Host Third Quarter 2024 Earnings Conference Call and Webcast on November 6, 2024, at 8:00 a.m. Eastern Time
globenewswire.com23 October 2024 Sentiment: POSITIVE

BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024.

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024
globenewswire.com15 September 2024 Sentiment: POSITIVE

Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was

Lantheus Appoints Julie Eastland as New Board Member
globenewswire.com05 September 2024 Sentiment: POSITIVE

BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
globenewswire.com28 August 2024 Sentiment: POSITIVE

BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.

Lantheus Reports Second Quarter 2024 Financial Results
globenewswire.com31 July 2024 Sentiment: POSITIVE

Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.

Why Lantheus Holdings Stock Is Skyrocketing Today
fool.com10 July 2024 Sentiment: POSITIVE

Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.

Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access
globenewswire.com10 July 2024 Sentiment: POSITIVE

BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to support patient access for Medicare beneficiaries.

Lantheus Appoints Jamie Spaeth as Chief People Officer
globenewswire.com08 July 2024 Sentiment: POSITIVE

BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer.

Why Lantheus Holdings (LNTH) is a Top Momentum Stock for the Long-Term
zacks.com24 June 2024 Sentiment: POSITIVE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

What type of business is Lantheus Holdings?

Lantheus Holdings, Inc. is one of the world leaders in the development, manufacturing, and commercialization of innovative agents and products for medical imaging, which help doctors in the diagnosis and treatment of cardiovascular and other diseases. Clinicians use the company's agents and products in a variety of imaging methods, including echocardiography and nuclear imaging. The company was founded in 1956, with its headquarters located in Billerica, Massachusetts, USA. The company's current portfolio consists of ten commercial products. The current products include contrast agents for ultrasound and medical radiopharmaceuticals for nuclear imaging.

What sector is Lantheus Holdings in?

Lantheus Holdings is in the Healthcare sector

What industry is Lantheus Holdings in?

Lantheus Holdings is in the Drug Manufacturers - Specialty & Generic industry

What country is Lantheus Holdings from?

Lantheus Holdings is headquartered in United States

When did Lantheus Holdings go public?

Lantheus Holdings initial public offering (IPO) was on 25 June 2015

What is Lantheus Holdings website?

https://www.lantheus.com

Is Lantheus Holdings in the S&P 500?

No, Lantheus Holdings is not included in the S&P 500 index

Is Lantheus Holdings in the NASDAQ 100?

No, Lantheus Holdings is not included in the NASDAQ 100 index

Is Lantheus Holdings in the Dow Jones?

No, Lantheus Holdings is not included in the Dow Jones index

When was Lantheus Holdings the previous earnings report?

No data

When does Lantheus Holdings earnings report?

The next expected earnings date for Lantheus Holdings is 06 November 2024